JP Morgan Chase’s Acceleron Pharma XLRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-20,000
Closed -$3.44M 7261
2021
Q3
$3.44M Buy
+20,000
New +$2.62M ﹤0.01% 3339
2020
Q3
Sell
-44,000
Closed -$4.19M 5939
2020
Q2
$4.19M Buy
+44,000
New +$4.24M ﹤0.01% 2590
2019
Q3
Sell
-30,000
Closed -$1.23M 6071
2019
Q2
$1.23M Sell
30,000
-10,000
-25% -$414K ﹤0.01% 3718
2019
Q1
$1.86M Buy
40,000
+10,000
+33% +$439K ﹤0.01% 3378
2018
Q4
$1.31M Buy
+30,000
New +$1.5M ﹤0.01% 3575
2018
Q1
Sell
-40,000
Closed -$1.7M 5721
2017
Q4
$1.7M Buy
+40,000
New +$1.5M ﹤0.01% 3413
2015
Q4
Sell
-40,000
Closed -$996K 4852
2015
Q3
$996K Buy
+40,000
New +$1.2M ﹤0.01% 3104

JP Morgan Chase's XLRN Position: Q4 2021 in Review

JP Morgan Chase sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 113,485 shares — an estimated $19.5M sold.

JP Morgan Chase first reported a position in XLRN in Q4 2013 and held it in 31 quarters. The position peaked at $40.9M in Q4 2015. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • JP Morgan Chase reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • JP Morgan Chase sold 113,485 Acceleron Pharma shares in Q4 2021, an estimated $19.5M.
  • JP Morgan Chase first reported a position in Acceleron Pharma in Q4 2013 and held it in 31 quarters.
  • JP Morgan Chase's Acceleron Pharma position peaked at $40.9M in Q4 2015.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on JP Morgan Chase's 13F filing for Q4 2021, filed 10 Feb 2022.